Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.
Bar-Or A, Wiendl H, Montalban X, Alvarez E, Davydovskaya M, Delgado SR, Evdoshenko EP, Giedraitiene N, Gross-Paju K, Haldre S, Herrman CE, Izquierdo G, Karelis G, Leutmezer F, Mares M, Meca-Lallana JE, Mickeviciene D, Nicholas J, Robertson DS, Sazonov DV, Sharlin K, Sundaram B, Totolyan N, Vachova M, Valis M, Bagger M, Häring DA, Ludwig I, Willi R, Zalesak M, Su W, Merschhemke M, Fox EJ. Bar-Or A, et al. Among authors: zalesak m. Mult Scler. 2022 May;28(6):910-924. doi: 10.1177/13524585211044479. Epub 2021 Oct 4. Mult Scler. 2022. PMID: 34605319 Free PMC article. Clinical Trial.
Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study.
Kira JI, Nakahara J, Sazonov DV, Kurosawa T, Tsumiyama I, Willi R, Zalesak M, Pingili R, Häring DA, Ramanathan K, Kieseier BC, Merschhemke M, Su W, Saida T. Kira JI, et al. Among authors: zalesak m. Mult Scler. 2022 Jul;28(8):1229-1238. doi: 10.1177/13524585211055934. Epub 2021 Nov 17. Mult Scler. 2022. PMID: 34787005 Clinical Trial.
Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS Trial.
Bar-Or A, Montalban X, Hu X, Kropshofer H, Kukkaro P, Coello N, Ludwig I, Willi R, Zalesak M, Ramanathan K, Kieseier BC, Häring DA, Bagger M, Fox E. Bar-Or A, et al. Among authors: zalesak m. Neurol Ther. 2023 Feb;12(1):303-317. doi: 10.1007/s40120-022-00427-8. Epub 2022 Dec 19. Neurol Ther. 2023. PMID: 36534274 Free PMC article.
The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease.
Lopez Lopez C, Tariot PN, Caputo A, Langbaum JB, Liu F, Riviere ME, Langlois C, Rouzade-Dominguez ML, Zalesak M, Hendrix S, Thomas RG, Viglietta V, Lenz R, Ryan JM, Graf A, Reiman EM. Lopez Lopez C, et al. Among authors: zalesak m. Alzheimers Dement (N Y). 2019 Jun 12;5:216-227. doi: 10.1016/j.trci.2019.02.005. eCollection 2019. Alzheimers Dement (N Y). 2019. PMID: 31211217 Free PMC article. Review.
Tracking residual organochlorine pesticides (OCPs) in green, herbal, and black tea leaves and infusions of commercially available tea products marketed in Poland.
Witczak A, Abdel-Gawad H, Zalesak M, Pohoryło A. Witczak A, et al. Among authors: zalesak m. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2018 Mar;35(3):479-486. doi: 10.1080/19440049.2017.1411614. Epub 2017 Dec 28. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2018. PMID: 29210611
Noninvasive approach to mend the broken heart: Is "remote conditioning" a promising strategy for application in humans?
Ravingerová T, Farkašová V, Griecsová L, Muráriková M, Carnická S, Lonek L, Ferko M, Slezak J, Zálešák M, Adameova A, Khandelwal VKM, Lazou A, Kolar F. Ravingerová T, et al. Among authors: zalesak m. Can J Physiol Pharmacol. 2017 Oct;95(10):1204-1212. doi: 10.1139/cjpp-2017-0200. Epub 2017 Jul 6. Can J Physiol Pharmacol. 2017. PMID: 28683229 Review.
27 results